# ADC Therapeutics SA (ADCT) · Edgar & Edgarette company card

> ADC Therapeutics (ADCT) grew revenue 14.9% in FY2025 to $81 million, operating margin -149% against a -3.8% median for pharmaceutical preparations, equity -57.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1771910 · fiscal year ended 2025-12-31 · 4 audited years read · [page](https://www.pops4.com/boards/company/ADCT) · [JSON](https://www.pops4.com/boards/company/ADCT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $81M |
| Revenue growth, 1 year | 14.9% |
| Revenue growth per year | -27.1% |
| Operating margin | -149.3% (prior year -184.4%) |
| Net margin | -175.3% |
| Operating cash flow | −$141M |
| Capital spending | $264,000 |
| Free cash flow | −$141M |
| Cash | $261M |
| Long-term debt | — |
| Total assets | $323M |
| Total equity | −$186M |
| Equity ÷ assets | -57.5% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -14.62 (distress zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -149.3% in FY2025; revenue is hard to predict: its 80% range is ±75%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $81.4M (FY2025). Experience: revenue up 14.9% on the year, down 27.1% a year over 3 years; operating margin -149.3%, up from -184.4%. Soundness: equity -57.5% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $27.6M and $189.7M next year (method v4.1: its own 3-year record of growth weighed at 40% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $29.7M to $177.3M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -149.3% against a -3.8% median; growth 14.9% against 13.7%.

Range logged 2026-10-14, receipt 4c65462c60b3ce87, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-07-02 ([filing](https://www.sec.gov/Archives/edgar/data/1771910/000095010326010195/0000950103-26-010195-index.htm))

## Recent filings

- 10-Q · filed 2026-11-09 · [filing](https://www.sec.gov/Archives/edgar/data/1771910/000162828026072178/0001628280-26-072178-index.htm)
- 8-K · filed 2026-11-09 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1771910/000162828026071899/0001628280-26-071899-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1771910/000095010326016945/0000950103-26-016945-index.htm)
- 8-K · filed 2026-10-13 · 1.01 Entry into a Material Definitive Agreement; 2.02 Results of Operations and Financial Condition; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1771910/000095010326015465/0000950103-26-015465-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1771910/000162828026056711/0001628280-26-056711-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/0000950103-26-012287-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001771910.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1771910

## Cite

POPS4, Edgar & Edgarette: ADC Therapeutics SA (ADCT) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/ADCT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

